(Q33903387)

29 July 2017

1 reference

title

Development of WHO guidelines on generalized cost-effectiveness analysis (English)

1 reference

World Health Organization

29 July 2017

0 references

cost-effectiveness analysis

1 reference

Murray CJ

1

1 reference

29 July 2017

Evans DB

series ordinal

2

1 reference

29 July 2017

Acharya A

series ordinal

3

1 reference

29 July 2017

Baltussen RM

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

29 July 2017

1 reference

29 July 2017

9

1 reference

29 July 2017

3

1 reference

29 July 2017

235-251

1 reference

Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost

29 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The costs and effectiveness of surveillance of communicable disease: a case study of HIV and AIDS in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Estimating country-specific cost-effectiveness from multinational clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost effectiveness of pramipexole in Parkinson's disease in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Some guidelines on the use of cost effectiveness league tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost-effectiveness analysis and capital costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The cost-effectiveness of endovascular repair versus open surgical repair of abdominal aortic aneurysms: A decision analysis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

On the decision rules of cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The decision rules of cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost-effectiveness analysis in a setting of budget constraints--is it equitable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Mathematical programming for the efficient allocation of health care resources.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Priority setting: lessons from Oregon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Rationing care in Oregon: the new accountability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Prioritising health services in an era of limits: the Oregon experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Five-hundred life-saving interventions and their cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

An alternative to QALYs: the saved young life equivalent (SAVE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Social evaluation of health care versus personal evaluation of health states. Evidence on the validity of four health-state scaling instruments using Norwegian and Australian surveys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The relevance of health state after treatment in prioritising between different patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Maximizing health benefits vs egalitarianism: an Australian survey of health issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Better benefits for health: plan to implement the central recommendation of the Acheson report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Primary health care in London--changes since the Acheson report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Intergenerational equity: an exploration of the 'fair innings' argument

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Rationing health care. Two tier service will develop on basis of ability to pay

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The role of ethics in the Clinton reform proposal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Ethical foundations of the Clinton administration's proposed health care system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The importance of perspective in the measurement of quality-adjusted life years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Issues in the cross-national assessment of health technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Some factors to consider when using the results of economic evaluation studies at the population level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost-effectiveness ratios: in a league of their own.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost-effectiveness league tables: think of the fans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Generalizing costs from trials. Analyzing center selection bias in a breast screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The generalisability of pharmacoeconomic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Resource costing for multinational neurologic clinical trials: methods and results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Making cost assessments based on RCTs more useful to decision-makers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Are differences in practitioners' acceptance of a quality assurance intervention related to their performance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

A case for the adoption of pharmacoeconomic guidelines in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The Danish approach to standards for economic evaluation methodologies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Economic evaluation of medical technologies: from theory to practice--the German perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The journal's policy on cost-effectiveness analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Methods of cost-effectiveness analysis: areas of consensus and debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Pharmacoeconomics: state of the art in 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Economic analyses of radiological procedures: a methodological evaluation of the medical literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Methodologic evaluation of the radiology cost-effectiveness literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Evaluation of pharmacoeconomic studies: utilization of a checklist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

A comparative review of pharmacoeconomic guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Incremental cost-effectiveness analysis: the optimal strategy depends on the strategy set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

The interpretation of results of economic evaluation: explicating the value of health

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Modeling malaria vaccines. I: New uses for old ideas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

On the use of mathematical models of malaria transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Epidemiological model and cost-effectiveness analysis of tuberculosis treatment programmes in Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Advanced breast cancer and its prevention by screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Cost-effectiveness league tables: More harm than good?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Reporting guidelines for economic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291099-1050%28200004%299%3A3%3C235%3A%3AAID-HEC502%3E3.0.CO%3B2-O

10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference